SNY

Over the past six months (March to September 2026), Sanofi's stock experienced fluctuations, losing 0.89% over 61 trading days, with a 12-month decline of 10.32%. Key events included a strong Q2 2026 earnings beat driven by new pharma launches and Dupixent growth. In September 2026, Sanofi announced an R&D reset under new leadership, emphasizing disciplined pipeline review, external innovation, and the termination or reassessment of several late-stage programs. The company reported a significant impairment of intangible assets of €1,031 million in Q2 2026. Sanofi also engaged in strategic partnerships, taking a 26.4% stake in Cheplapharm, and completed several acquisitions between 2023 and 2025. Vaccine sales growth was expected to be slightly negative in 2026, mainly in the second half, due to usual seasonality, and Dupixent faces a lawsuit threat and biosimilar risk post-2031.